Report #2851445

Received Jul 28, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: MO
Recovered: Unknown
Vaccinated: Jan 1, 2025
Onset: Jan 1, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	UNK	—	—

Symptoms (1)

Interchange of vaccine products

Symptom narrative

Patient Received 1 Dose of HEPLISAV-B, and Then 1 Dose of Engerix; Initial report received on 16-Jul-2025. A medical assistant reported that a patient (age, gender, race, ethnicity not provided) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and received ENGERIX-B as the second dose. No medical history or concomitant medications were reported. On Jan-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot #, expiration date, NDC #, route, and site not provided). On an unknown date, after having been vaccinated with HEPLISAV-B, the patient received ENGERIX-B (lot #, expiration date, and NDC # rote, and site not provided). No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.